- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Greenwich LifeSciences: Phase-III-Studie wird auf City of Hope-Standorte ausgeweitet | 2 | Investing.com Deutsch | ||
| Do | Greenwich LifeSciences expands Phase III trial to City of Hope sites | 1 | Investing.com | ||
| Do | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01 | 3 | GlobeNewswire (USA) | ||
| GREENWICH LIFESCIENCES Aktie jetzt für 0€ handeln | |||||
| Mi | Greenwich LifeSciences to present trial data at AACR meeting | 1 | Investing.com | ||
| Mi | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Upcoming AACR Meeting | 1 | GlobeNewswire (USA) | ||
| Di | Greenwich LifeSciences reports reduced cancer recurrence in trial | 14 | Investing.com | ||
| Di | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01 | 130 | GlobeNewswire (Europe) | STAFFORD, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial... ► Artikel lesen | |
| Mo | Greenwich LifeSciences begins using commercial GP2 at US sites | 1 | Investing.com | ||
| Mo | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01 | 99 | GlobeNewswire (Europe) | STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial... ► Artikel lesen | |
| 03.03. | Greenwich LifeSciences reports 33% rise in trial screening rate | 2 | Investing.com | ||
| 03.03. | Greenwich LifeSciences: Screening-Rate für Brustkrebsstudie steigt um 33 % | 1 | Investing.com Deutsch | ||
| 03.03. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01 | 611 | GlobeNewswire (Europe) | STAFFORD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial... ► Artikel lesen | |
| 24.02. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026 | 2 | GlobeNewswire (USA) | ||
| 24.02. | Greenwich LifeSciences abstracts accepted at AACR 2026 meeting | 2 | Investing.com | ||
| 27.01. | Greenwich LifeSciences reports $12.5 million cash balance | 2 | Investing.com | ||
| 27.01. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy | 181 | GlobeNewswire (Europe) | STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 26.01. | Greenwich LifeSciences-Aktie: Wird sie zum Impfstoff-Überflieger? | 321 | sharedeals.de | Die Aktie von Greenwich LifeSciences sorgte kürzlich mit einem Unternehmensupdate für neue Aufmerksamkeit. Ausschlaggebend ist weniger ein klinischer Meilenstein als vielmehr ein regulatorischer Fortschritt... ► Artikel lesen | |
| 22.01. | GLSI Stock Surges After FDA Clears Use Of Commercial GP2 In Phase III Trial | 1 | RTTNews | ||
| 22.01. | Greenwich LifeSciences: Kurssprung nach FDA-Zulassung für kommerzielle Charge in Phase-III-Studie | 16 | Investing.com Deutsch | ||
| 22.01. | Greenwich LifeSciences surges as FDA clears commercially manufactured product candidate | 1 | Seeking Alpha |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,30 | +0,26 % | Bioxyne vs. BioNTech: Australisches MDMA-Biotech hebt Prognose nach starkem Halbjahr an | ||
| VIKING THERAPEUTICS | 27,835 | -0,50 % | Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics | ||
| KUROS BIOSCIENCES | 25,960 | +1,64 % | Kuros schreibt 2025 schwarze Zahlen | Schlieren - Das Biotechunternehmen Kuros hat Wort gehalten und den Umsatz 2025 um mehr als 70 Prozent gesteigert. Getragen wurde die Entwicklung erneut durch das Knochenersatzprodukt MagnetOs. Konkret... ► Artikel lesen | |
| ABIVAX | 105,80 | -0,19 % | Abivax-Aktie: Die Entscheidung naht | Während sich bei Abivax derzeit alles um eine potenzielle und möglicherweise sehr lukrative Übernahme zu drehen scheint, ist klar: Auch als eigenständiges Biotechunternehmen sind die Perspektiven für... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,540 | -0,90 % | Cardiff Oncology, Inc.: Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer | ||
| IOVANCE BIOTHERAPEUTICS | 3,261 | +0,98 % | Iovance Biotherapeutics: Aufsichtsratsmitglied Wendy Yarno kündigt Rücktritt an | ||
| DENALI THERAPEUTICS | 17,375 | +1,64 % | Denali Therapeutics Inc.: Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndromeDNL126 (ETV:SGSH) Phase 1/2 preliminary... ► Artikel lesen | |
| ARGENX | 577,60 | +0,21 % | argenx SE: argenx announces Annual General Meeting of Shareholders on May 6, 2026 | ||
| CAPRICOR | 25,100 | -1,18 % | CAPRICOR THERAPEUTICS, INC. - 10-K, Annual Report | ||
| INSMED | 121,00 | +2,54 % | Artisan Small Cap Fund Sold Insmed (INSM) on Valuation Consideration | ||
| ZEVRA THERAPEUTICS | 8,150 | +1,88 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen | |
| REVOLUTION MEDICINES | 83,00 | 0,00 % | Revolution Medicines, Inc.: Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting | ||
| SYNDAX PHARMACEUTICALS | 21,000 | 0,00 % | Syndax Pharmaceuticals, Inc.: Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | - Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 - - Revuforj- (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 - - Niktimvo... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 11,520 | 0,00 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,520 | -1,34 % | J&J files trade secret lawsuit against former oncology employee linked to Summit Therapeutics |
GREENWICH LIFESCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,15 % bei einem Aktienkurs von 24,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GREENWICH LIFESCIENCES INC finden Sie auf Wallstreet Online.